Thomas Carpenter is Professor of Pediatrics (Endocrinology) and Professor of Orthopaedics and Rehabilitation at the Yale School of Medicine. He received his medical degree and general pediatrics training at the University of Alabama prior to fellowship training in endocrinology at Boston Children's Hospital.
Dr. Carpenter's career-long interests have focused on the investigation and management of metabolic bone diseases in children, particularly X-Linked Hypophosphatemia. At Yale for over 25 years, he has been very active in the Yale Bone Program throughout this time. In addition to directing the YC-XLH and Yale's Pediatric Metabolic Bone Clinic, Dr. Carpenter serves as director of the Hospital Research Unit (Yale's CTSA-supported clinical research facility), and directs the Physiology Core of the NIH-sponsored Yale Core Center for Musculoskeletal Diseases.
Author of over 100 articles, reviews, and book chapters related to his interests in metabolic bone disease in children, Dr. Carpenter is regularly invited to speak at national and international meetings and currently serves as a scientific advisor to The XLH Network, Inc., the primary support/advocacy group for people affected by or interested in X-Linked Hypophosphatemia.
In addition to leading the YC-XLH, Dr. Carpenter is the principal investigator for the Center's clinical research project, "The role of parathyroid hormone in the pathogenesis of skeletal disease in X-linked hypophosphatemic rickets (XLH)."
Karl Insogna, Professor in Medicine (Endocrinology) at Yale School of Medicine, has a long-standing clinical and research interest in X-Linked Hypophosphatemia. He took his undergraduate and medical degrees from the University of Connecticut and did his clinical training in Internal Medicine at the University of Rochester's Strong Memorial Hospital. He completed his Fellowship in Endocrinology and Metabolism at Yale University after which he joined Yale's faculty, where he has since remained.
Dr. Insogna is Director of the Yale Bone Center, a major multi-disciplinary treatment center for adults with metabolic bone disorders. He also directs the NIH-funded Yale Core Center for Musculoskeletal Disorders. He is a member of the American Society for Clinical Investigation and a fellow of the American Association for the Advancement of Science. He has published extensively on the topics of skeletal health and disease.
Dr. Insogna directs the YC-XLH Pilot and Feasibility Program and is co-investigator, with Dr. Carpenter, for the YC-XLH clinical project, "The role of parathyroid hormone in the pathogenesis of skeletal disease in X-linked hypophosphatemic rickets (XLH)."